(Total Views: 774)
Posted On: 07/30/2020 8:12:28 PM
Post# of 153903
Re-listened to m2m update -
Day 3 vs 0 positive results in primary end point.
Day 3,7,14 positive results in NEWS2 Secondary end point.
Need for oxygen or mechanical ventilation - leronlimab beat placebo arm Secondary end point.
Add this onto our 64% SAE reduction in treatment arm versus placebo.
Top line data due in for publication in about 10 days.
I'm going to go out on a limb and say they wouldn't mention these unless there was statistical significance associated with the data.
This is 4 strong aspects of efficacy in leronlimab SO FAR. It's likely they will find more.
Day 3 vs 0 positive results in primary end point.
Day 3,7,14 positive results in NEWS2 Secondary end point.
Need for oxygen or mechanical ventilation - leronlimab beat placebo arm Secondary end point.
Add this onto our 64% SAE reduction in treatment arm versus placebo.
Top line data due in for publication in about 10 days.
I'm going to go out on a limb and say they wouldn't mention these unless there was statistical significance associated with the data.
This is 4 strong aspects of efficacy in leronlimab SO FAR. It's likely they will find more.
(4)
(0)
